Peijia Medical (沛嘉医疗) Pre-IPO: Deserves Valuation Premium for the TAVR Late Comer
Peijia Medical is a leading domestic player in the transcatheter valve therapeutic medical device market and the neurointerventional procedural...
654 Views
Peijia Medical IPO Initiation: Let's Have a Heart-To-Heart
Peijia Medical (1740651D CH) is a leading transcatheter heart valve medical device company in China. It has filed for a Hong Kong IPO and is...
486 Views
Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level
Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...
711 Views
Venus Medtech IPO: Fairly Valued and More Room for Share Price to Grow
In our previous insight on Venus Medtech IPO Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth , we discussed the...
680 Views
Venus Medtech IPO: Valuation Tempting at the Low-End
Venus MedTech (2500 HK) is a leading transcatheter heart valve medical device company in China. Venus has launched a Hong Kong IPO to raise up to...
683 Views